Abstract
PTEN tumor suppressor opposes the PI3K/Akt signaling pathway in the cytoplasm and maintains chromosomal integrity in the nucleus. Nucleus–cytoplasm shuttling of PTEN is regulated by ubiquitylation, SUMOylation and phosphorylation, and nuclear PTEN has been proposed to exhibit tumor-suppressive functions. Here we show that PTEN is conjugated by Nedd8 under high glucose conditions, which induces PTEN nuclear import without effects on PTEN stability. PTEN neddylation is promoted by the XIAP ligase and removed by the NEDP1 deneddylase. We identify Lys197 and Lys402 as major neddylation sites on PTEN. Neddylated PTEN accumulates predominantly in the nucleus and promotes rather than suppresses cell proliferation and metabolism. The nuclear neddylated PTEN dephosphorylates the fatty acid synthase (FASN) protein, inhibits the TRIM21-mediated ubiquitylation and degradation of FASN, and then promotes de novo fatty acid synthesis. In human breast cancer tissues, neddylated PTEN correlates with tumor progression and poor prognosis. Therefore, we demonstrate a previously unidentified pool of nuclear PTEN in the Nedd8-conjugated form and an unexpected tumor-promoting role of neddylated PTEN.
Similar content being viewed by others
Introduction
PTEN encodes a membrane-bound protein phosphatase with potent tumor suppressor activity.1,2,3 Loss of PTEN function leads to excessive activation of the PI3K/Akt oncogenic pathway, which stimulates cell growth and survival.4,5,6 Recent studies have suggested that nuclear PTEN exhibits a complementary mechanism with cytoplasmic PTEN to suppress tumor development.7 Nuclear PTEN interacts with centromeres to maintain their stability,8 is involved in DNA repair,9 and regulates gene transcription.10,11,12,13 Mono-ubiquitination of PTEN by Nedd4 and deubiquitination by HAUSP/USP7 contribute to the regulation of the nuclear import and export of PTEN.14,15 SUMOylation of PTEN also controls its nuclear localization. In cells exposed to genotoxic stress, SUMOylated PTEN was rapidly exported from the nucleus, a process that was dependent on the protein kinase ATM.16
Nedd8 is a ubiquitin-like protein that is covalently conjugated to substrates in a manner similar to ubiquitin.17 The neddylation system consists of an activating enzyme (E1, a heterologous dimer composed of UBA3 and NAE1/APP-BP1), two conjugating enzymes (E2s, UBE2M/Ubc12 and UBE2F) and a variety of E3 ligases.18 Neddylation primarily targets Cullin–RING ubiquitin ligases for their activation, and an increasing number of non-Cullin targets of Nedd8 have been identified. Neddylation can be removed by deneddylases, including NEDP1 and JAB1/CSN5.19,20 An inhibitor of E1, named MLN4924 (also known as pevonedistat), has been evaluated in a series of phase I/II/III clinical trials both alone and in combination with chemo-/radiotherapies.21,1. MMTV-PyMT mice (PyMT/WT mice, FVB/N background) were kindly gifted by Professor Mingyao Liu from East China Normal University. The db/db mice were purchased from Shanghai Model Organisms Center, Inc. The NAE inhibitor MLN4924 (HY-70062), proteasome inhibitor MG132 (HY-13259), XIAP inhibitor Embelin (HY-17473), p300/CBP inhibitor ICBP112 (HY-19541), 2-Deoxy-d-glucose (a glucose analog and a competitive inhibitor of glucose metabolism) (2-DG, HY-13966) were purchased from MCE. Cisplatin (P4394) and methyl methane sulfonate (MMS) (129925) were purchased from Sigma Aldrich. SUMOylation inhibitor 2-D08 (S8696) was purchased from Selleck. The antibody details were listed in Supplementary information, Table S2.
Cell culture and transfections
MCF-7, MDA-MB-231, MDA-MB-468, 4T1, HEK293T cell lines were purchased from ATCC, and authenticated by STR profiling and tested for mycoplasma contamination by GENEWIZ. MCF-10A (a human non-tumorigenic breast epithelial cell line) cells were kindly gifted by Qinong Ye from Bei**g Institute of Biotechnology. HEK293T NEDP1+/+ and NEDP1–/– cells were kindly gifted by Professor **aofeng Zheng from Peking University. MCF-7, MDB-MA-468, HEK293T, HEK293T NEDP1+/+ and NEDP1–/– cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS). MDA-MB-231 cells were cultured in Leibovit’s L-15 medium supplemented with 10% FBS. MCF-10A cells were cultured in mammary epithelial cell growth medium (Promo Cell, C-39115) with 10% horse serum, New Zealand Origin (Invitrogen, 16050-114). Mouse 4T1 cells were cultured with MEM medium supplemented with 10% FBS. Cells were transfected with various plasmids using TuboFect (Thermo Fisher Scientific, R0531), Sage LipoPlusTM, Lipofectamine 3000 (Invitrogen, L3000001) according to the manufacturer’s protocol.
Immunoprecipitation and immunoblotting
For immunoprecipitation assays, cells were lysed in EBC lysis buffer (0.5% NP-40, 50 mM Tris, pH 7.6, 120 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF and 1 mM β-mercaptoethanol) supplemented with protease inhibitor cocktail (Roche, 11836170001). Immunoprecipitations were performed using the indicated primary antibody and protein A/G agarose beads (Santa Cruz, sc-2003) at 4 °C. The immunoprecipitants were washed at least three times in NETN lysis buffer (150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl, pH7.8, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride) before being resolved by SDS-PAGE and immunoblotted with indicated antibodies.
RNA interference
siRNAs against Mdm2 (sc-29394), Roc1 (sc-44072), c-Cbl (sc-29242), XIAP (sc-37508), Nedd4-1 (sc-41079), WWP2 (sc-40362), WWP1 (sc-40366), NEDP1 (sc-44452) were purchased from Santa Cruz Biotechnology. Sequence information of the siRNA, shRNA and sgRNA is provided in Supplementary information, Table S3.
In vivo modification assays
Cells were solubilized in modified lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 1% SDS, 1 mM Na3VO4, 1 mM DTT and 10 mM NaF) supplemented with a protease inhibitor cocktail. The cell lysate was incubated at 60 °C for 10 min. The lysate was then diluted 10 times with modified lysis buffer without SDS and incubated with the indicated antibody for 3 h at 4 °C before adding Protein A/G-plus Agarose (Santa Cruz, sc-2003). Then the lysate was rotated gently for 8 h at 4 °C. The immunoprecipitants were washed at least three times in wash buffer (50 mM Tris, pH7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 1 mM DTT and 10 mM NaF). Proteins were analyzed by western blotting with indicated antibodies.
In vitro modification assays
GST-PTEN and His-XIAP were expressed in Escherichia coli BL21 (DE3). For the Neddylation assay, 0.5 μg of GST-PTEN, 0.5 μg of His-XIAP were incubated with 2 μg of Nedd8, 10 ng of E1 (APPBP1-UBA3) and 200 ng of E2 (Ubc12) in a total reaction volume of 20 μL Nedd8 conjugation Rxn Buffer Kit (BostonBiochem, SK-20). Nedd8 (UL-812), Nedd8 E1 (APPBP1/UBA3) (E-313), Ubc12 (A-655) were purchased from BostonBiochem. Samples were incubated at 30 °C for 1 h, and reactions were terminated with SDS-PAGE loading buffer before western blotting.
His pull-down by Ni-NTA columns
Cells were collected and resuspended in binding buffer (6 M guanidine HCl, 0.1 M Na2HPO4, 0.1 M NaH2PO4, 0.01 M Tris (pH8.0), 10 mM β-mercaptoethanol, 5 mM NEM, 5 mM imidazole) and incubated with Ni2+-NTA Superflow Cartridges (QIAGEN, 17-5318-02) at 4 °C for 12 h. Immunoblotting was performed using indicated antibodies.
Generation of knockout cells
The knockout cell lines were generated using the CRISPR–Cas9 method. CRISPR guide sequences targeting PTEN, UBA3, Ubc12, XIAP and NEDP1 were designed by software at http://crispr.mit.edu and cloned into lenti-Crispr pXPR_001. The sgRNA sequences were listed in Supplementary information, Table S3. MCF-7 and MCF-10A cells were co-transfected with the Lenti-Crispr vector and packaging plasmids pVSVg and psPAX2. Puromycin-resistant single cells were plated in a 96-well dish to screen for positive monoclonal cells.
Fluorescence microscopy
After fixation with 4% paraformaldehyde and permeabilization in 0.2% Triton X-100 (PBS), cells were incubated with the indicated antibodies for 12 h at 4 °C, followed by incubation with goat anti-rabbit IgG H&L Alexa Fluor 488 or 594 antibody for 1 h at 37 °C. The nuclei were stained with DAPI, and images were visualized with a Zeiss LSM 510 Meta inverted confocal microscope.
Cell fractionation
Nuclear fractions were prepared by using the Minute TM Nuclear and Cytoplasmic Extraction Reagents Kit (Invent biotech, SC-003) according to the manufacturer’s protocol.
Real-time PCR
Total RNA was isolated and converted to cDNA using the ReverTra Ace® (Toyobo, TRT-101). Quantitative PCR reactions were carried out using SYBR Green PCR master mix (Toyobo, QPK201). Primers were shown in Supplementary information, Table S4.
Cell proliferation assay
Cells were plated on 96-well plates (1000 cells per well). After adding Cell Counting Kit-8 (Do**do, CK04) to the wells for 1 h, cell numbers were measured at 450 nm. Each cell line was set up in 4 replicate wells, and the experiment was repeated three times.
Colony formation assay
Cells were seeded into 6-well tissue culture plate with 6000 cells per well. Plates were incubated at 37 °C and 5% CO2 and colonies were scored 21 days after preparation.
Cell migration assay
The assay was performed in an invasion chamber consisting of a 24-well tissue culture plate with 12 cell culture inserts (Becton-Dickinson). A cell suspension in serum-free culture medium (5 × 104 cells per well) was added to the inserts, and each insert was placed in the lower chamber containing 10% FBS culture medium. Cells were allowed to migrate for 24 h in a humidified chamber at 37 °C with 5% CO2. Then filter was removed and fixed with 4% formaldehyde for 20 min. Cells located in the lower filter were stained with 0.1% crystal violet for 15 min and photographed.
Tumor growth in mice
The experimental procedures in mice have been approved by the Animal Care and Use Committee of Academy of Military and Medical Sciences. BALB/c nude mice (6-week old, 18.0 ± 2.0 g) were obtained from Shanghai Laboratory Animal Center (SLAC, China). Diabetic db/db mice (6-week old, 35 ± 2 g) were obtained from Shanghai Model Organisms Center, Inc. (SMOC, China). Cells (5 × 106 per mouse) were inoculated subcutaneously into the right flank of the mice. Tumor size was measured every 3 days and converted to TV according to the following formula: TV (mm3) = (a × b2)/2, where a and b are the largest and smallest diameters, respectively. All animals were killed 4 weeks after injection, and the transplanted tumors were removed, weighed and fixed.
Cohort and immunohistochemistry
The breast tissue microarrays were purchased from Shanghai Biochip Company (HBre-Duc170Sur-01, HBre-Duc139Sur-01, HBre-Duc090Sur-01) and Shanghai Superbiotek Company (BRC1601). HBre-Duc170Sur-01 and HBre-Duc090Sur-01 were immunostained with NEDP1, UBA3 and PTEN (Supplementary information, Data S4 and S6). HBre-Duc139Sur-01 and HBre-Duc090Sur-01 were immunostained with Nedd8-PTEN K402 antibody (Supplementary information, Data S5). The patient’s pathological information in HBre-Duc139Sur-01 is fully included in the HBre-Duc170Sur-01 array. Breast cancer tumors and matched adjacent normal tissues were approved by the department of breast and thyroid Surgery at the Second People’s Hospital of Shenzhen (14 cases in Supplementary information, Data S7). BRC1601 were used for multicolor fluorescence immunohistochemistry with neddylated PTEN on K402, FASN, UBA3, XIAP and PTEN antibodies (Supplementary information, Data S8). All staining was assessed by a quantitative imaging method; the percentage of immunostaining and the staining intensity were recorded. An H-score was calculated using the following formula: H-score = Σ (PI × I) = (percentage of cells of weak intensity × 1) + (percentage of cells of moderate intensity × 2) + (percentage of cells of strong intensity × 3). PI indicates the percentage of positive cells versus all cells.
ELISA assay
The quantitation of FASN level was performed using ELISA assay kit (Biomatik, EKU04054) according to the manufacturer’s instructions.
LC-MS/MS analysis
Proteins in IP samples were precipitated with IP buffer (0.5% NP-40, 50 mM Tris, pH 7.6, 120 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF and 1 mM b-mercaptoethanol) and then washed three times with IP buffer. The samples from in-gel digestion were analyzed on a ThermoTM Q Exactive (Thermo Fisher Scientific) interfaced with an EASY-nLC 1000 UPLC system (Thermo Fisher Scientific). The tryptic peptides were dissolved in 0.1% FA, directly loaded onto a reversed-phase precolumn (Acclaim PepMap 100, Thermo). Peptide separation was performed using a reversed phase analytical column (Acclaim PepMap RSLC, Thermo). The gradient was comprised of an increase from 6% to 25% solvent B (0.1% FA in 98% ACN) over 16 min, 25% to 40% over 6 min and climbing to 80% in 4 min then holding at 80% for the last 4 min, all at a constant flow rate of 320 nL/min on an EASY-nLC 1000 UPLC system. The peptides were subjected to NSI source followed by tandem mass spectrometry (MS/MS) in Q ExactiveTM (Thermo) coupled online to the UPLC. Intact peptides were detected in the orbitrap at a resolution of 70,000. Peptides were selected for MS/MS using NCE setting as 28; ion fragments were detected in the orbitrap at a resolution of 17,500. A data-dependent procedure that alternated between one MS scan followed by 20 MS/MS scans was applied for the top 20 precursor ions above a threshold ion count of 5E3 in the MS survey scan with 15.0 s dynamic exclusion. The electrospray voltage applied was 2.0 kV. Automatic gain control (AGC) was used to prevent overfilling of the orbitrap; 5E4 ions were accumulated for generation of MS/MS spectra. For MS scans, the m/z scan range was 350 to 1800. The resulting MS/MS data were processed using Mascot search engine (v.2.3.0). Tandem mass spectra were searched against Swissport Human database. Trypsin/P was specified as cleavage enzyme allowing up to 2 missing cleavages. Mass error was set to 10 ppm for precursor ions and 0.02 Da for fragment ions. Carbamidomethyl on Cys were specified as fixed modification and oxidation on Met, acetylation on Protein N-term were specified as variable modifications. Peptide ion score was set ≥ 20. Protein identification data (accession numbers, peptides observed, sequence coverage) are available in Supplementary information, Data S1 and S3, respectively. All raw data and search results have been deposited to the PRIDE database (http://www.iprox.org/index). The accession numbers are PXD011368 (Supplementary information, Data S1), PXD021544 (Supplementary information, Data S2) and PXD011395 (Supplementary information, Data S3).
GC-FID/MS analysis of fatty acids
Fatty acid composition was measured in the methylated forms. About 5 mg protein lysed from indicated cells was homogenized with 5% methanol sulfate and 0.2% BHT methanol at 90–95 °C water bath for 1.5 h. Then Saturated saline and N-hexane were added before centrifugation 5 min at 4 °C. Methyl-19-carbonate was added and vortexed for 10 s. After methylated, fatty acid composition was analyzed using 7890B Gas Chromatograph (GC) 5977 A Mass Selective Detector (MSD) (Agilent Technologies, USA) which was equipped with a flame ionization detector (FID) and a mass spectrometer carrying an electron impact (EI) ion source. An Agilent DB-225 capillary GC column (10 m, 0.1 mm ID, 0.1 μm film thickness) was used with 1 μL sample injection volume and a splitter (1:30). The temperature of injection port and detector was set at 230 °C. The column temperature was programmed with 55 °C for 1 min, and then increased to 205 °C with a rate of 30 °C per min. Column temperature was kept at 205 °C for following 3 min and increased to 230 °C at 5 °C per min. For identification, the methylated fatty acids were compared with a chromatogram from a mixture of 37 known standards and then confirmed with their mass spectral data. Each fatty acid was quantified with the FID data by comparing its signal integrals with peak integrals of internal standards. These data were expressed as μmol of fatty acids per gram of tissue, which are available in Supplementary information, Data S9.
Micro-PET/CT
Before 18F-FDG administration, mice were deprived of food for 8–12 h. 18F-FDG (11.1 MBq (300 mCi) in 0.2 mL) was injected through the tail vein. Micro-PET/CT imaging was started 1 h after 18F-FDG injection. Micro-PET/CT images was performed on a Super Nova PET/CT scanner (PINGSENG Healthcare (Kunshan) Inc.). For micro-PET/CT imaging, all mice were subjected to isoflurane anesthesia (1%–2% in 100% oxygen) on a temperature self-adjust tube to maintain body temperature throughout the procedure. Mice were visually monitored for breathing and any other signs of distress throughout the full imaging period. The images were reconstructed using a three-dimensional ordered subsets expectation maximum algorithm (OSEM) without attenuation correction. For data analysis, the region of interest (ROI) was manually drawn to cover the whole tumor on fused images.
Further information of materials and methods is listed in Supplementary information, Data S10.
Ethics statement
All animals were handled in strict accordance to the “Guide for the Care and Use of Laboratory Animals” and the “Principles for the Utilization and Care of Vertebrate Animals”, and all animal work was approved by the Institutional Animal Care and Use Committee (IACUC) at the Bei**g Institute of Lifeomics. The clinical samples were approved by the department of breast and thyroid surgery at the Second People’s Hospital of Shenzhen. Informed consent was obtained from all subjects or their relatives.
Statistical analysis
All data were representative of no less than three independent experiments. All data were presented as means ± SD. Data were analyzed using SPSS 19.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA). The differences between groups were assessed by Student’s t-test. The correlations were analyzed using Pearson correlation test. A value of P < 0.05 was considered to be statistically significant.
Data availability
For IP-MS, all raw data and search results have been deposited to the PRIDE database (http://www.iprox.org/index) with the accession number: PXD011368 (Supplementary information, Data S1); PXD021544 (Supplementary information, Data S2); PXD011395 (Supplementary information, Data S3). The authors declare that all the relevant data supporting the findings of this study are available within the article and its Supplementary information files, or from the corresponding author on reasonable request.
Change history
29 January 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41422-021-00470-4
References
Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283–296 (2012).
Naguib, A. et al. PTEN functions by recruitment to cytoplasmic vesicles. Mol. Cell 58, 255–268 (2015).
Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29–39 (1998).
Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 133, 403–414 (2008).
Hollander, M. C., Blumenthal, G. M. & Dennis, P. A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11, 289–301 (2011).
Lee, J. O. et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99, 323–334 (1999).
Lee, Y. R., Chen, M. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat. Rev. Mol. Cell Biol. 19, 547–562 (2018).
Shen, W. H. et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157–170 (2007).
Puc, J. & Parsons, R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 4, 927–929 (2005).
Li, A. G. et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Cell 23, 575–587 (2006).
Ying, H. et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 1, 158–169 (2011).
Wang, J. et al. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation. Cancer Res. 65, 6601–6611 (2005).
Song, M. S. et al. Immunohistochemical tumor-suppressive complex in a phosphatase-independent manner. Cell 144, 187–199 (2011).
Trotman, L. C. et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128, 141–156 (2007).
Song, M. S. et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455, 813–817 (2008).
Bassi, C. et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 341, 395–399 (2013).
Kerscher, O., Felberbaum, R. & Hochstrasser, M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Ann. Rev. Cell Dev. Biol. 22, 159–180 (2006).
Enchev, R. I., Schulman, B. A. & Peter, M. Protein neddylation: beyond cullin-RING ligases. Nat. Rev. Mol. Cell Biol. 16, 30–44 (2015).
Mendoza, H. M. et al. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. J. Biol. Chem. 278, 25637–25643 (2003).
Cope, G. A. et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298, 608–611 (2002).
Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732–736 (2009).
Abidi, N. & **rodimas, D. P. Regulation of cancer-related pathways by protein NEDDylation and strategies for the use of NEDD8 inhibitors in the clinic. Endocr. Relat. Cancer 22, T55–T70 (2015).
Zhou, L. & Jia, L. Targeting Protein Neddylation for Cancer Therapy. Adv. Exp. Med. Biol. 1217, 297–315 (2020).
Finicle, B. T., Jayashankar, V. & Edinger, A. L. Nutrient scavenging in cancer. Nat. Rev. Cancer 18, 619–633 (2018).
Hu, Q. et al. LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition. Cell Res. 29, 286–304 (2019).
Liang, H. et al. PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism. Cell Metab. 19, 836–848 (2014).
Liang, H. et al. PTENβ is an alternatively translated isoform of PTEN that regulates rDNA transcription. Nat. Commun. 8, 14771 (2017).
**e, P. et al. The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis. Nat. Commun. 5, 3733 (2014).
Ohki, Y. et al. The mechanism of poly-NEDD8 chain formation in vitro. Biochem. Biophys. Res. Commun. 381, 443–447 (2009).
Keuss, M. J. et al. Unanchored tri-NEDD8 inhibits PARP-1 to protect from oxid-ative stress induced cell death. EMBO J. 38, e100024 (2019).
Hori, T. et al. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 18, 6829–6834 (1999).
Zhuang, M., Guan, S., Wang, H., Burlingame, A. L. & Wells, J. A. Substrates of IAP ubiquitin ligases identified with a designed orthogonal E3 ligase, the NEDDylator. Mol. Cell 49, 273–282 (2013).
Van Themsche, C., Leblanc, V., Parent, S. & Asselin, E. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J. Biol. Chem. 284, 20462–20466 (2009).
Lloyd, C. T. et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128, 141–156 (2007).
Lee, Y. R. et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science 364, eaau0159 (2019).
Maddika, S. et al. WWP2 Is an E3 ubiquitin Ligase for PTEN. Nat. Cell Biol. 13, 728–733 (2011).
Harper, J. W. Neddylating the guardian; Mdm2 catalyzed conjugation of Nedd8 to p53. Cell 118, 2–4 (2004).
Zuo, W. et al. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor. Mol. Cell 49, 499–510 (2013).
Hu, J., McCall, C. M., Ohta, T. & **ong, Y. Targeted ubiquitination of CDT1 by the DDB1 CUL4A-ROC1 ligase in response to DNA damage. Nat. Cell Biol. 6, 1003–1009 (2004).
Nikolovska-Coleska, Z. et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47, 2430–2440 (2004).
Siegel, C., Li, J., Liu, F., Benashski, S. E. & McCullough, L. D. miR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia. Proc. Natl. Acad. Sci. USA 108, 11662–11667 (2011).
Yang, J. R.-M. et al. Characterization of PTEN mutations in brain cancer reveals that Pten mono-ubiquitination promotes protein stability and nuclear localization. Oncogene 36, 3673–3685 (2017).
Valiente, M. et al. Binding of PTEN to specific PDZ domains contributes to PTEN protein stability and phosphorylation by microtubule-associated serine/threonine kinases. J. Biol. Chem. 280, 28936–28943 (2005).
Huang, G. et al. SCCRO (DCUN1D1) promotes nuclear translocation and assembly of the neddylation E3 complex. J. Biol. Chem. 286, 10297–10304 (2012).
Jia, X. et al. Neddylation inactivation facilitates FOXO3a nuclear export to suppress estrogen receptor transcription and improve fulvestrant sensitivity. Clin. Cancer Res. 25, 3658–3672 (2019).
Beck, M. & Hurt, E. The nuclear pore complex: understanding its function through structural insight. Nat. Rev. Mol. Cell Biol. 18, 73–89 (2017).
Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E. & Mann, M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol. 15, 536–550 (2014).
Ikenoue, T., Inoki, K., Zhao, B. & Guan, K. L. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 68, 6908–6912 (2008).
Liu, F. et al. PTEN enters the nucleus by diffusion. J. Cell Biochem. 96, 221–234 (2005).
Guan, J., Zhao, Q. & Mao, W. Nuclear PTEN interferes with binding of Ku70 at double-strand breaks through post-translational poly(ADP-ribosyl)ation. Biochim. Biophys. Acta. 1863, 3106–3115 (2016).
Malaney, P., Palumbo, E., Semidey-Hurtado, J. & Hardee, J. PTEN physically Interacts with and regulates E2F1-mediated transcription in lung cancer. Cell Cycle 17, 947–962 (2018).
Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763–777 (2007).
Lin, H. P. et al. Destabilization of fatty acid synthase by acetylation inhibits de novo lipogenesis and tumor cell growth. Cancer Res. 76, 6924–6936 (2016).
Perren, A. et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 155, 1253–1260 (1999).
Goldhirsch, A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24, 2206–2223 (2013).
Chen, J. H. et al. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Autophagy 11, 239–252 (2015).
Wu, Y. et al. PTEN phosphorylation and nuclear export mediate free fatty acid-induced oxidative stress. Antioxid. Redox Signal. 20, 1382–1395 (2014).
Gu, Y. et al. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood 123, 3269–3276 (2014).
Barbier-Torres, L. et al. Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer. Oncotarget 6, 2509–2523 (2015).
Crunkhorn, S. Breast cancer: FASN inhibitor increases survival. Nat. Rev. Drug Discov. 15, 532 (2016).
lwarawrah, Y. et al. Fasnall, a selective FASN inhibitor, shows potent anti-tumor activity in the MMTV-Neu model of HER2+ breast cancer. Cell Chem. Biol. 23, 678–688 (2016).
Acknowledgements
We thank Drs. Mian Wu (University of Science and Technology of China, Anhui Province, China), **aofeng Zheng (Peking University, Bei**g, China), Mingyao Liu (East China Normal University, Shanghai, China), Qinong Ye (Bei**g Institute of Biotechnology) for kindly providing materials. This work was jointly supported by the National Key R&D Program of China (2017YFA0505602), Chinese National Basic Research Programs (2015CB910401), Chinese National Natural Science Foundation Project (31670774, 31971229), Bei**g Natural Science Foundation Project (Z151100003915083), Open Project Program of the State Key Laboratory of Proteomics (SKLP-O201901), Support Project of High-level Teachers in Bei**g Municipal Universities in the Period of 13th Five-year Plan (CIT&TCD201704097) and Bei**g excellent talents training project.
Author information
Authors and Affiliations
Contributions
The project was conceived by L.Z. The experiments were designed by L.Z., P.X. and F.H. Most of the modification experiments were performed by P.X. The cell biology function experiments were contributed by Z.P., P.X., and M.D. The animal experiments were contributed by Z.P., H.L. and X.Z. The breast cancer sample collection and immunohistochemical analysis were contributed by Z.P., Y.C. and Y.T. The statistical analysis was completed by Z.P., Z.L., C.H.L. and C.-P.C. Data were analyzed by L.Z., P.X. and Z.P. The manuscript was written by L.Z. and P.X.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
**e, P., Peng, Z., Chen, Y. et al. Neddylation of PTEN regulates its nuclear import and promotes tumor development. Cell Res 31, 291–311 (2021). https://doi.org/10.1038/s41422-020-00443-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41422-020-00443-z
- Springer Nature Singapore Pte Ltd.
This article is cited by
-
Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways
Biomarker Research (2024)
-
Integrated analysis reveals the regulatory mechanism of the neddylation inhibitor MLN4924 on the metabolic dysregulation in rabbit granulosa cells
BMC Genomics (2024)
-
Protein neddylation and its role in health and diseases
Signal Transduction and Targeted Therapy (2024)
-
RNA m6A methylation and regulatory proteins in pulmonary arterial hypertension
Hypertension Research (2024)
-
The implications of FASN in immune cell biology and related diseases
Cell Death & Disease (2024)